Skip to content

Application and evaluation of neurotrophic agents targeted injection for zoster associated pain

Efficacy evaluation of neurotrophic agents targeted injection for zoster associated pain

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200064254
Enrollment
Unknown
Registered
2022-10-01
Start date
2022-10-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Zoster associated pain

Interventions

2:Ultrasound-guided targeted injection methylcobalamin
1:oral methylcobalamin+Ultrasound-guided targeted injection Lidocaine

Sponsors

Shanghai Tenth People's Hospital, Affiliated Tenth People's Hospital of Tongji University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 72 Years

Inclusion criteria

Inclusion criteria: Patients were included in this study on the basis of the following criteria: a confirmed diagnosis of HN lasting for at least 15-180 days, older than 50 yrs, experienced cutaneous and/or subcutaneous pain of the dermatomal area or adjacent cutaneous dermatomes temporally and spatially associated with their HZ rash, and a worst pain score of 4 or greater on an 11-point NRS in the past 24 hrs.

Exclusion criteria

Exclusion criteria: Subjects who met the following criteria were excluded from this study: unilateral dermatomal pain in the vesicular region for less than 120 days with diffusely distributed neuropathic pain or significant pain outside the target regions; any clinically significant medical condition or laboratory abnormality; any cognitive impairment; and cardiac pacemakers, severe general diseases, hypersensitivity to cobalamin, or use of any topical analgesic or nerve blocker within 10 days before the baseline visit. Although the use of topical analgesics was considered an exclusion criterion, patients were allowed to continue oral analgesics that they had previously taken for pain control at the same dose. No change of medications was permitted, but dose reduction or complete discontinuation of analgesics was allowed during the course of the study.

Design outcomes

Primary

MeasureTime frame
pain intensity;pain intensity;

Secondary

MeasureTime frame
e Patients’ Global Impression of Change (PGIC) scale;ADL and health-related QoL;QST;Sensory conduction of Ad fibers;pain evoked potentials of Ad fibers;

Countries

CHINA

Contacts

Public ContactGang Xu

Affiliated Tenth People's Hospital of Tongji University

shsykf@yeah.net+86 18917683646

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026